Fulgent Genetics (NASDAQ:FLGT) Updates FY25 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY25 earnings guidance on Friday. The company provided earnings per share guidance of $(0.65) for the period, compared to the consensus earnings per share estimate of ($0.15). The company issued revenue guidance of $310.0 million, compared to the consensus revenue estimate of $324.65 million. Fulgent Genetics also updated its FY 2025 guidance to -0.650–0.650 EPS.

Fulgent Genetics Stock Down 3.4 %

Shares of NASDAQ:FLGT opened at $15.69 on Friday. The company has a market capitalization of $479.91 million, a P/E ratio of -2.84 and a beta of 1.39. Fulgent Genetics has a 52-week low of $15.38 and a 52-week high of $25.11. The stock’s fifty day simple moving average is $17.37 and its 200-day simple moving average is $19.55.

Wall Street Analyst Weigh In

Several research firms have issued reports on FLGT. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Piper Sandler cut their price target on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, November 11th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.